{"title":"靶向Mucin-1的肿瘤疫苗研究进展","authors":"Jianwei Gao, Hui Xiao","doi":"10.3760/CMA.J.ISSN.1673-436X.2020.04.009","DOIUrl":null,"url":null,"abstract":"Mucin-1 (MUC1) is a highly glycosylated transmembrane protein that is expressed on the surface of most epithelial cells and maintains homeostasis in epithelial barriers.MUC1 is over-expressed and abnormally glycosylated in various malignant tumors and can promote tumorigenesis and metastasis.Aberrant glycosylation and expression of tumor-associated MUC1 result in the generation of cancer-specific epitopes, providing opportunities for vaccine design.Currently, MUC1-targeted vaccines have been extensively tested in human clinical trials and can be classified into four categories: peptide-conjugate, glycan, viral vector and dendritic cell vaccines.TG4010, a viral vector vaccine, has revealed significant clinical efficacy in patients with advanced non-small-cell lung cancer in combination with chemotherapy.This review summarized the current clinical trails of MUC1-targeted tumor vaccines. \n \n \nKey words: \nCancer vaccines; Immunotherapy; Mucin-1; TG4010","PeriodicalId":10004,"journal":{"name":"Chinese Journal of Asthma","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in research of cancer vaccines targeting Mucin-1\",\"authors\":\"Jianwei Gao, Hui Xiao\",\"doi\":\"10.3760/CMA.J.ISSN.1673-436X.2020.04.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mucin-1 (MUC1) is a highly glycosylated transmembrane protein that is expressed on the surface of most epithelial cells and maintains homeostasis in epithelial barriers.MUC1 is over-expressed and abnormally glycosylated in various malignant tumors and can promote tumorigenesis and metastasis.Aberrant glycosylation and expression of tumor-associated MUC1 result in the generation of cancer-specific epitopes, providing opportunities for vaccine design.Currently, MUC1-targeted vaccines have been extensively tested in human clinical trials and can be classified into four categories: peptide-conjugate, glycan, viral vector and dendritic cell vaccines.TG4010, a viral vector vaccine, has revealed significant clinical efficacy in patients with advanced non-small-cell lung cancer in combination with chemotherapy.This review summarized the current clinical trails of MUC1-targeted tumor vaccines. \\n \\n \\nKey words: \\nCancer vaccines; Immunotherapy; Mucin-1; TG4010\",\"PeriodicalId\":10004,\"journal\":{\"name\":\"Chinese Journal of Asthma\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese Journal of Asthma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-436X.2020.04.009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Asthma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-436X.2020.04.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Advances in research of cancer vaccines targeting Mucin-1
Mucin-1 (MUC1) is a highly glycosylated transmembrane protein that is expressed on the surface of most epithelial cells and maintains homeostasis in epithelial barriers.MUC1 is over-expressed and abnormally glycosylated in various malignant tumors and can promote tumorigenesis and metastasis.Aberrant glycosylation and expression of tumor-associated MUC1 result in the generation of cancer-specific epitopes, providing opportunities for vaccine design.Currently, MUC1-targeted vaccines have been extensively tested in human clinical trials and can be classified into four categories: peptide-conjugate, glycan, viral vector and dendritic cell vaccines.TG4010, a viral vector vaccine, has revealed significant clinical efficacy in patients with advanced non-small-cell lung cancer in combination with chemotherapy.This review summarized the current clinical trails of MUC1-targeted tumor vaccines.
Key words:
Cancer vaccines; Immunotherapy; Mucin-1; TG4010
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
